George Gushue
Pulmonary Disease · Trenton, NJNPI 1093761678
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 264 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 30.2% of the total. Reporting peaked in 2019 at $1,622 and has fallen 99.1% since, to $14 in 2022.
Across 264 payments — averaging $13.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$650
- Boehringer Ingelheim$389
- Sunovion Pharmaceuticals Inc.$188
- Genentech USA, Inc.$161
- Sanofi$161
- plus $886 from 22 others
What the payments were for
- Food & beverage$3,40498%
- Education$822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 91 | $1,051 |
| AstraZeneca | 29 | $650 |
| Boehringer Ingelheim | 38 | $389 |
| Sunovion Pharmaceuticals Inc. | 16 | $188 |
| Genentech USA, Inc. | 15 | $161 |
| Sanofi | 15 | $161 |
| Philips North America LLC | 10 | $158 |
| Astellas Pharma US Inc | 1 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $67 |
| Actelion Pharmaceuticals US, Inc. | 5 | $65 |
| Mylan Specialty L.p. | 4 | $56 |
| Pfizer | 4 | $54 |
| Mallinckrodt Enterprises LLC | 4 | $54 |
| Grifols USA, LLC | 3 | $41 |
| Vanda Pharmaceuticals Inc. | 3 | $40 |
| Jazz Pharmaceuticals Inc. | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| Harmony Biosciences LLC | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Novartis | 2 | $26 |
| Optinose US, Inc. | 2 | $25 |
| Shire North American Group Inc | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Electromed, Inc. | 1 | $13 |
| Insmed, Inc. | 1 | $12 |
| Advanced Respiratory, Inc | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$133
- SYMBICORT$133
- TRELEGY ELLIPTA$125
How this compares
$3,486 in reported general payments places this provider in the 60th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Trenton
- Anthony RickettiTrenton$225K
- Arthur PaciaTrenton$14K
- Joseph HoffmanPark Ridge$1.1M
- Reynold PanettieriNew Brunswick$1M
- Robert SussmanSummit$551K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
- Richard MillerNewark$328K
- Jason ShatkinParamus$282K
- Jeffrey MiskoffManasquan$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.